Emma Barroso Fernández
I finished my Biology studies at the University of Barcelona in 2003. In 2006 I completed an Experimental Master in Pharmacy in the Pharmacology department under the supervision of Dr. Manuel Vázquez Carrera. A year later, in 2007, Dr. Vázquez Carrera gave me the opportunity to start my doctoral studies with a scholarship funded by the Bosch i Gimpera Institute. In January 2011 I obtained my title of Excellent Cum Laude PhD with the work entitled "Efecte de l'activació de PPARβ/δ sobre l'oxidació d'àcids grassos i el procés inflamatori" from which two original articles emerged (Endocrinology 2011 and Biochemichal Pharmacology 2011) with an impact index of 4,459 and 4,705 respectively and belonging to Q1.
Subsequently, from February 2011 to the present I have been part of the research team of Dr. Vázquez Carrera with a Research Staff contract by CIBERDEM (Ciber for Diabetes and Metabolic Diseases, ISCIII) where I have dedicated myself to the study of molecular pathways involved in hyperlipidemia, inflammation and insulin resistance being some of the most relevant works: Molecular Metabolism 2018, Diabetes 2016, Biochimica et Biophysica Acta 2015 and Biochemica et Biophysica acta 2013. Also during this time I have collaborated with other research teams of which original publications have also emerged (Petrov et at. Biochimica et Biophysica Acta 2015, Pedros et at. Biochimica et Biophysica Acta 2014 i Vilà et al. PlosOne 2012).
On the other hand, since 2016 I am also a 3 + 3 Associate Professor at the University of Barcelona teaching classes in the Pharmacognosy subject.
Professional network profiles
- Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya F and Vazquez M SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1a-LIPIN 1 pathway and increasing CD36 through Nrf2. CELL COMMUN SIGNAL . 18(1): 147-147.
- Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. TRENDS PHARMACOL SCI . 41(3): 199-208.
- Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation. signal transduction and targeted therapy . 5(1): 14-14.